

Dr. Daniel Obrecht



After a PhD in organic chemistry obtained from the University of Zurich (1983), D. Obrecht spent two years of postdoctoral studies working in Prof. R. E. Ireland's group at the California Institute of Technology on the total synthesis of avermectin. He then joined the Central Research Laboratories of F. Hoffmann-La Roche in Basle where he worked on several drug discovery projects. In 1989 he started a project with the aim to find small molecule peptidomimetics of exposed protein epitopes. In 1993 he was awarded Roche Lecturer, and 1994 he started a combinatorial chemistry project which he headed in 1996. End of 1996 he co-founded Polyphor with his brother Dr. Jean-Pierre Obrecht. The main expertises of D. Obrecht are synthetic organic chemistry with particular emphasis on macrocycles, medicinal chemistry and drug discovery. He is currently CSO of the the company Polyphor and author of 65 publications and 32 patents, including key patents on the Protein Epitope Mimetics (PEM) Technology and products.

J. W. Vrijbloed, D. Obrecht, S. Lociuoro, F. Gombert, Ch. Ludin, J. A. Robinson, A. Lederer, S. Shivaprasad, WO 2004033489 (**2004-04-22**);
Template-fixed peptidomimetics with antibacterial activity

N. Srinivas, P. Jetter, B. J. Ueberbacher, M. Werneburg, K. Zerbe, J. Steinmann, B. Van der Meijden, F. Bernardini, A. Lederer, R. L. Dias, P. E. Misson, H. Henze, J. Zumbunn, F. O. Gombert, D. Obrecht, P. Hunziker, S. Schauer, U. Ziegler, A. Käch, L. Eberl, K. Riedel, S. J. DeMarco, J. A. Robinson, *Science* **2010**, 327, 1010-1013;
Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa

D. Obrecht, E. Chevalier, K. Moehle, J. A. Robinson, *Drug Disc. Today: Technologies* **2012**, 9, e63-e69;
□-*Hairpin protein epitope mimetic technology in drug discovery*

D. Obrecht, J. A. Robinson, F. Bernardini, C. Bisang, S. J. DeMarco, K. Moehle, F. O. Gombert, *Curr. Med. Chem.* **2009**, 16, 42-65;
Recent Progress in the Discovery of Macrocyclic Compounds as Potential Anti-Infective Therapeutics